From: Entrevestor
By: Avery Mullen
Date: Feb. 1, 2024
Myomar is joining the Emergence bioscience incubator and PragmaClin is joining the U.K.’s Plug and Play Health accelerator.
wo Atlantic Canadian medtech companies have joined life sciences accelerators.
St. John’s-based PragmaClin Research, which is developing technology to help monitor Parkinson’s patients, is joining the United Kingdom’s Plug and Play Health accelerator, part of an international network of similar programs. And Halifax’s Myomar Molecular, which has developed a urine test to monitor muscle degeneration, is joining Emergence, the bioscience incubator headquartered in Charlottetown.
“As we initiate our regulatory journey and commercialization phase, we are looking forward to working with Emergence to speed up and facilitate this process,” said Myomar CEO Rafaela Andrade in a statement.
“We have nearly 900 people signed up for our beta tests and we are working hard to put the technology in the market.”